Tag Archives: Myles Minter

William Blair Thinks Prevail Therapeutics’ Stock is Going to Recover

In a report issued on November 24, Myles Minter from William Blair reiterated a Buy rating on Prevail Therapeutics (PRVL – Research Report). The company’s shares closed last Friday at $10.03, close to its 52-week low of $9.02. According to

William Blair Remains a Buy on Aptinyx (APTX)

William Blair analyst Myles Minter maintained a Buy rating on Aptinyx (APTX – Research Report) on August 5. The company’s shares closed last Wednesday at $3.38. According to TipRanks.com, Minter is a 4-star analyst with an average return of 15.0%

William Blair Reaffirms Their Buy Rating on Axsome Therapeutics (AXSM)

In a report issued on July 13, Myles Minter from William Blair reiterated a Buy rating on Axsome Therapeutics (AXSM – Research Report). The company’s shares closed last Wednesday at $71.25. According to TipRanks.com, Minter is a 4-star analyst with

Axsome Therapeutics (AXSM) Received its Third Buy in a Row

After Guggenheim and H.C. Wainwright gave Axsome Therapeutics (NASDAQ: AXSM) a Buy rating last month, the company received another Buy, this time from William Blair. Analyst Myles Minter reiterated a Buy rating on Axsome Therapeutics yesterday. The company’s shares closed

Analysts Conflicted on These Healthcare Names: Minerva Neurosciences (NASDAQ: NERV), Beyondspring (NASDAQ: BYSI) and Zogenix (NASDAQ: ZGNX)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Minerva Neurosciences (NERV – Research Report), Beyondspring (BYSI – Research Report) and Zogenix (ZGNX – Research Report). Minerva Neurosciences (NERV) William Blair analyst Myles Minter

Analysts Offer Insights on Healthcare Companies: and Axsome Therapeutics (NASDAQ: AXSM)

There’s a lot to be optimistic about in the Healthcare sector as 1 analysts just weighed in on and Axsome Therapeutics (AXSM – Research Report) with bullish sentiments. Axsome Therapeutics (AXSM) William Blair analyst Myles Minter reiterated a Buy rating